GB2589306A — Use of cannabidiol preparations in the treatment of fragile X syndrome

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of Fragile X syndrome (FXS). The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids, wherein the less than or equal to 2% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); cannabidiol-C1 (CBD-C1); cannabidivarin CBDV); and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of trans-THC and cis-THC. The CBD present may be isolated from cannabis plant material or at least a portion of at least one of the cannabinoids present in the CBD preparation is isolated from cannabis plant material. The CBD preparation may be for use in the treatment of seizures, cognitive symptoms or behaviour associated with Fragile X syndrome. The CBD may be present as a synthetic preparation or at least a portion of at least one of the cannabinoids present in the CBD preparation is prepared synthetically. The dose of CBD in the prepartum may be greater than 5 mg/kg/day. The dose of CBD may be 20 mg/kg/day, 25 mg/kg/day or 50 mg/kg/day. A method of treating FXS comprising administering a CBD preparation to the subject in need is also disclosed.